Post-IPO Equity Funded Startups
Among the 50 most recent “Post-IPO Equity” rounds shown, the largest disclosed amount is Vaxcyte’s $600M on 2022-10-26, which dwarfs the rest of the disclo…
Among the 50 most recent “Post-IPO Equity” rounds shown, the largest disclosed amount is Vaxcyte’s $600M on 2022-10-26, which dwarfs the rest of the disclosed rounds (the next-highest disclosed amounts visible include Portland General Electric at $375M on 2022-10-25 and Recursion Pharmaceuticals at $150M on 2022-10-25). The list is also highly concentrated by time: 27 of the 50 rounds fall between 2022-10-17 and 2022-10-26, with the date range running from 2022-10-10 through 2022-10-27.
Sector-wise, Biotechnology appears most frequently (9 entries), and the geography is somewhat hub-like at the country/region level (multiple entries in Canada, alongside several U.S. and U.K./European listings). Disclosures are uneven: 12 of 50 rounds are marked “undisclosed,” which affects how consistently sizes can be compared; among the disclosed amounts, the smallest is Ridgeline Minerals at $450K on 2022-10-18, far below most other figures.
Most recent rounds
50 shownRelated listings
Frequently asked
What stands out on round size in these post-IPO equity deals, and how extreme is it versus the rest?
Vaxcyte’s $600M round (2022-10-26) is the clear size outlier among disclosed amounts: Portland General Electric is $375M (2022-10-25) and Recursion Pharmaceuticals is $150M (2022-10-25), while many other disclosed entries sit well below $100M (e.g., ChromaDex at $3M on 2022-10-14 and Ridgeline Minerals at $450K on 2022-10-18).
Is there a temporal cluster in the most recent post-IPO equity rounds shown?
Yes. Of the 50 rows, 27 close between 2022-10-17 and 2022-10-26, including multiple same-day entries like 2022-10-20 (Calix $38M, Suzlon Energy $145M, and Eevia Health $2M) and 2022-10-24 (Kootenay Silver $4M and Taysha Gene Therapies $50M).
Which sectors appear most often, and are they concentrated in particular sizes?
Biotechnology is the most frequent sector in the list with 9 entries (e.g., Vaxcyte $600M on 2022-10-26, Biohaven Pharmaceutical $302M on 2022-10-20, and Taysha Gene Therapies $50M on 2022-10-24). Other frequently appearing categories include Natural Resources (5 entries) and Energy (4 entries), but Biotechnology contains both the largest disclosed round ($600M) and many mid-to-high figures (e.g., Denali Therapeutics $275M on 2022-10-19).
How much of the list is “undisclosed,” and does it distort comparisons of size?
12 of 50 rounds are labeled “undisclosed” (e.g., Bittium on 2022-10-26 and Vertiv on 2022-10-20), so any “largest/smallest” comparisons rely on fewer disclosed datapoints. Still, the disclosed minimum is very low—Ridgeline Minerals at $450K (2022-10-18)—while large disclosed outliers exist in multiple sectors (e.g., Portland General Electric $375M on 2022-10-25).
Are there specific geographies that recur more than others across this snapshot?
The U.S. shows repeated entries across multiple dates (e.g., Recursion Pharmaceuticals $150M on 2022-10-25; Denali Therapeutics $275M on 2022-10-19; Bright Health Group $175M on 2022-10-11). Canada also recurs with several listings, such as Liberty Defense (Vancouver) at $4M on 2022-10-27 and Kootenay Silver (Vancouver) at $4M on 2022-10-24, indicating clustering at the country/city level rather than a single company repeating.
What do the newest and oldest entries imply about momentum across the window?
The newest row is Liberty Defense at $4M on 2022-10-27, while the oldest date shown is 2022-10-10, including Dragonfly Energy $150M (2022-10-10) and immunmatics biotechnologies $110M (2022-10-10). With activity spread across the entire 2022-10-10 to 2022-10-27 window, the concentration appears strongest in the 2022-10-17 to 2022-10-26 band rather than at a single endpoint.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.